SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), with strongest activity at ERRα[1][11]. In murine studies, acute administration activated an aerobic-exercise transcriptional program, increased mitochondrial respiration and fatty-acid oxidation in skeletal muscle, and improved endurance capacity and cardiometabolic phenotypes[3]. The compound acts as an “exercise mimetic” by engaging metabolic pathways typically activated during physical training, without requiring the mechanical stress of actual exercise. However, all evidence to date is preclinical—no human trials have been conducted.
